Denali Therapeutics Inc. Common Stock DNLI
i
Market dataready · fetched 2026-11-12T01:34:33.166Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:11:58.556200211Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T01:34:32.603615+00:00
Denali Therapeutics Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 15.12 | 268.5% | 29.0% | |||
| 25Δ | 16.47 | 221.5% | 22.3% | |||
| 30Δ | 21.73 | 91.2% | 12.7% | 17.65 | 182.5% | 16.7% |
| 35Δ | 21.21 | 84.2% | 10.4% | 18.29 | 169.8% | 14.3% |
| 40Δ | 20.70 | 77.2% | 8.2% | 18.93 | 157.0% | 11.8% |
| 45Δ | 20.18 | 70.2% | 5.9% | 19.56 | 144.2% | 9.4% |
| 50Δ | 19.76 | 70.9% | 4.8% | 20.10 | 132.7% | 7.5% |
| 55Δ | 19.38 | 76.0% | 4.3% | 20.40 | 124.1% | 6.6% |
| 60Δ | 19.00 | 81.0% | 3.9% | 20.71 | 115.5% | 5.7% |
| 65Δ | 18.62 | 86.1% | 3.4% | 21.01 | 106.8% | 4.8% |
| 70Δ | 18.24 | 91.1% | 2.9% | 21.31 | 98.2% | 3.9% |
| 75Δ | 17.86 | 96.2% | 2.5% | 21.62 | 89.5% | 3.0% |
| 80Δ | 17.44 | 102.2% | 2.0% | 21.92 | 80.9% | 2.1% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.12
- IV
- 268.5%
- B/E move
- 29.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.47
- IV
- 221.5%
- B/E move
- 22.3%
30Δ
- Pseudo strike
- 21.73
- IV
- 91.2%
- B/E move
- 12.7%
- Pseudo strike
- 17.65
- IV
- 182.5%
- B/E move
- 16.7%
35Δ
- Pseudo strike
- 21.21
- IV
- 84.2%
- B/E move
- 10.4%
- Pseudo strike
- 18.29
- IV
- 169.8%
- B/E move
- 14.3%
40Δ
- Pseudo strike
- 20.70
- IV
- 77.2%
- B/E move
- 8.2%
- Pseudo strike
- 18.93
- IV
- 157.0%
- B/E move
- 11.8%
45Δ
- Pseudo strike
- 20.18
- IV
- 70.2%
- B/E move
- 5.9%
- Pseudo strike
- 19.56
- IV
- 144.2%
- B/E move
- 9.4%
50Δ
- Pseudo strike
- 19.76
- IV
- 70.9%
- B/E move
- 4.8%
- Pseudo strike
- 20.10
- IV
- 132.7%
- B/E move
- 7.5%
55Δ
- Pseudo strike
- 19.38
- IV
- 76.0%
- B/E move
- 4.3%
- Pseudo strike
- 20.40
- IV
- 124.1%
- B/E move
- 6.6%
60Δ
- Pseudo strike
- 19.00
- IV
- 81.0%
- B/E move
- 3.9%
- Pseudo strike
- 20.71
- IV
- 115.5%
- B/E move
- 5.7%
65Δ
- Pseudo strike
- 18.62
- IV
- 86.1%
- B/E move
- 3.4%
- Pseudo strike
- 21.01
- IV
- 106.8%
- B/E move
- 4.8%
70Δ
- Pseudo strike
- 18.24
- IV
- 91.1%
- B/E move
- 2.9%
- Pseudo strike
- 21.31
- IV
- 98.2%
- B/E move
- 3.9%
75Δ
- Pseudo strike
- 17.86
- IV
- 96.2%
- B/E move
- 2.5%
- Pseudo strike
- 21.62
- IV
- 89.5%
- B/E move
- 3.0%
80Δ
- Pseudo strike
- 17.44
- IV
- 102.2%
- B/E move
- 2.0%
- Pseudo strike
- 21.92
- IV
- 80.9%
- B/E move
- 2.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 76.00% | |
| 74.62% | |
| 75.08% | |
| 75.23% | |
| 78.53% | |
| 84.63% | |
| 80.00% | |
| 77.65% | |
| 84.18% | |
| 80.24% |
Biotechnology
DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and…
More →DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha…
More →DRUG
Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies for central nervous system…
More →DSGN
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad,…
More →DTIL
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
More →DYN
Description unavailable
More →